Answers are grounded in this paper and cite their sources.
The advent of novel therapies has significantly changed the therapeutic landscape in multiple myeloma (MM). However, MM remains largely incurable and patients undergo disease relapse frequently after a short remission period. This is partly because MM is characterized by the loss of critical mediators of immune surveillance and the development of an immunologic milieu that fosters both disease progression and resistance to therapy. In fact, novel anti-MM agents such as bortezomib and lenalidomide exert many of their effects via immunomodulation in addition to direct cytotoxic effect against myeloma cells. 1 Despite this, there is a lack of clinically useful immune biomarkers that could reflect both the baseline host immune status and predict clinical outcomes. 2 Using retrospective data from a large cohort, we show that the absolute lymphocyte count (ALC) to the absolute monocyte count (AMC) ratio in the peripheral blood (PB) serves as a powerful prognostic immune biomarker in newly diagnosed MM patients and may reflect the immunologic status of these patients. We also correlate this biomarker with known adverse cytogenetics in MM.
No takes yet. Share an insight, caveat, or question.
Dosani et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: